

Bartolome Celli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10986934/publications.pdf>

Version: 2024-02-01

100
papers

18,935
citations

31976

53
h-index

37204

96
g-index

103
all docs

103
docs citations

103
times ranked

12460
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2007, 356, 775-789. | 27.0 | 2,963 |
| 2 | A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2008, 359, 1543-1554. | 27.0 | 1,969 |
| 3 | American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1390-1413. | 5.6 | 1,644 |
| 4 | Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2015, 373, 111-122. | 27.0 | 974 |
| 5 | Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research, 2010, 11, 122. | 3.6 | 952 |
| 6 | Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 155-161. | 5.6 | 946 |
| 7 | Changes in Forced Expiratory Volume in 1 Second over Time in COPD. New England Journal of Medicine, 2011, 365, 1184-1192. | 27.0 | 811 |
| 8 | Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLoS ONE, 2012, 7, e37483. | 2.5 | 633 |
| 9 | Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet, The, 2009, 374, 1171-1178. | 13.7 | 430 |
| 10 | Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respiratory Medicine, 2013, 107, 1376-1384. | 2.9 | 328 |
| 11 | Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research, 2009, 10, 59. | 3.6 | 287 |
| 12 | Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes *. Chest, 2003, 124, 1743-1748. | 0.8 | 278 |
| 13 | Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 382-386. | 5.6 | 257 |
| 14 | Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 948-955. | 5.6 | 252 |
| 15 | Prevalence and Progression of Osteoporosis in Patients With COPD. Chest, 2009, 136, 1456-1465. | 0.8 | 240 |
| 16 | The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respiratory Medicine, the, 2013, 1, 129-136. | 10.7 | 224 |
| 17 | A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Human Molecular Genetics, 2012, 21, 947-957. | 2.9 | 216 |
| 18 | Power of Outcome Measurements to Detect Clinically Significant Changes in Pulmonary Rehabilitation of Patients With COPD. Chest, 2002, 121, 1092-1098. | 0.8 | 214 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest, 2006, 130, 647-656. | 0.8 | 205 |
| 20 | Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2012, 13, 291-297. | 2.5 | 193 |
| 21 | Cardiovascular Safety of Tiotropium in Patients With COPD. Chest, 2010, 137, 20-30. | 0.8 | 185 |
| 22 | Cardiovascular events in patients with COPD: TORCH Study results. Thorax, 2010, 65, 719-725. | 5.6 | 177 |
| 23 | Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940. | 13.7 | 176 |
| 24 | Symptom-Limited Stair Climbing as a Predictor of Postoperative Cardiopulmonary Complications After High-Risk Surgery. Chest, 2001, 120, 1147-1151. | 0.8 | 174 |
| 25 | Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax, 2007, 62, 595-601. | 5.6 | 170 |
| 26 | Addressing the Complexity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1129-1137. | 5.6 | 166 |
| 27 | Inhaled corticosteroids in COPD: friend or foe?. European Respiratory Journal, 2018, 52, 1801219. | 6.7 | 166 |
| 28 | Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. European Respiratory Journal, 2013, 42, 636-646. | 6.7 | 164 |
| 29 | Impact and prevention of severe exacerbations of COPD: a review of the evidence. International Journal of COPD, 2017, Volume 12, 2891-2908. | 2.3 | 162 |
| 30 | Gene Expression Profiling of Human Lung Tissue from Smokers with Severe Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 601-610. | 2.9 | 159 |
| 31 | Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 317-322. | 5.6 | 157 |
| 32 | Clinical Trial Design Considerations in Assessing Long-Term Functional Impacts of Tiotropium in COPD: The Uplift Trial. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2004, 1, 303-312. | 1.6 | 152 |
| 33 | Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax, 2014, 69, 718-723. | 5.6 | 151 |
| 34 | Once-Daily Umeclidinium/Vilanterol 125/25 µg Therapy in COPD. Chest, 2014, 145, 981-991. | 0.8 | 142 |
| 35 | Exacerbation frequency and course of COPD. International Journal of COPD, 2012, 7, 653. | 2.3 | 138 |
| 36 | Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1022-1030. | 5.6 | 130 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 303-312. | 3.2 | 126 |
| 38 | Lessons from ECLIPSE: a review of COPD biomarkers. <i>Thorax</i> , 2014, 69, 666-672. | 5.6 | 125 |
| 39 | Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1238-1247. | 5.6 | 117 |
| 40 | Estimation of Ventilatory Reserve by Stair Climbing. <i>Chest</i> , 1993, 104, 1378-1383. | 0.8 | 106 |
| 41 | Biologic Lung Volume Reduction in Advanced Upper Lobe Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 791-798. | 5.6 | 103 |
| 42 | Acclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. <i>Respiratory Medicine</i> , 2011, 105, 580-587. | 2.9 | 96 |
| 43 | The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1483-1493. | 5.6 | 83 |
| 44 | Bias due to withdrawal in long-term randomised trials in COPD: Evidence from the TORCH study. <i>Clinical Respiratory Journal</i> , 2011, 5, 44-49. | 1.6 | 78 |
| 45 | What does endotyping mean for treatment in chronic obstructive pulmonary disease?. <i>Lancet</i> , The, 2017, 390, 980-987. | 13.7 | 78 |
| 46 | Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. <i>Respiratory Research</i> , 2011, 12, 6. | 3.6 | 76 |
| 47 | DNA methylation profiling in human lung tissue identifies genes associated with COPD. <i>Epigenetics</i> , 2016, 11, 730-739. | 2.7 | 73 |
| 48 | Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT® trial. <i>Respiratory Medicine</i> , 2010, 104, 1495-1504. | 2.9 | 68 |
| 49 | The COPD Biomarker Qualification Consortium (CBQC). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 367-377. | 1.6 | 67 |
| 50 | Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT® Trial. <i>Lung</i> , 2011, 189, 261-268. | 3.3 | 64 |
| 51 | Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 463-469. | 5.6 | 63 |
| 52 | Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , 2020, 158, 952-964. | 0.8 | 62 |
| 53 | Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. <i>Thorax</i> , 2011, 66, 489-495. | 5.6 | 61 |
| 54 | Rapid Lung Function Decline in Smokers Is a Risk Factor for COPD and Is Attenuated by Angiotensin-Converting Enzyme Inhibitor Use. <i>Chest</i> , 2014, 145, 695-703. | 0.8 | 60 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. <i>European Respiratory Journal</i> , 2014, 44, 324-331. | 6.7 | 57 |
| 56 | Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. <i>International Journal of COPD</i> , 2018, Volume 13, 3971-3981. | 2.3 | 56 |
| 57 | Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 651-666. | 5.6 | 49 |
| 58 | Telomere shortening and accelerated aging in COPD: findings from the BODE cohort. <i>Respiratory Research</i> , 2017, 18, 59. | 3.6 | 46 |
| 59 | Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. <i>Respirology</i> , 2011, 16, 825-835. | 2.3 | 43 |
| 60 | Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. <i>Human Molecular Genetics</i> , 2015, 24, 1200-1210. | 2.9 | 43 |
| 61 | Natural history of COPD: gaps and opportunities. <i>ERJ Open Research</i> , 2017, 3, 00117-2017. | 2.6 | 40 |
| 62 | Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 1, 229-238. | 0.7 | 38 |
| 63 | The Challenge of Controlling the COPD Epidemic: Unmet Needs. <i>American Journal of Medicine</i> , 2018, 131, 1-6. | 1.5 | 33 |
| 64 | Time for a change: anticipating the diagnosis and treatment of COPD. <i>European Respiratory Journal</i> , 2020, 56, 2002104. | 6.7 | 33 |
| 65 | Use of Proteomic Patterns of Serum Biomarkers in Patients with Chronic Obstructive Pulmonary Disease: Correlation with Clinical Parameters. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 465-466. | 3.5 | 28 |
| 66 | Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015, 10, 549. | 2.3 | 26 |
| 67 | Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2021, 57, 2001339. | 6.7 | 26 |
| 68 | Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial. <i>Respiratory Research</i> , 2011, 12, 129. | 3.6 | 25 |
| 69 | Venous Admixture in COPD: Pathophysiology and Therapeutic Approaches. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008, 5, 376-381. | 1.6 | 24 |
| 70 | A diVlusive Shuffling Approach (ViStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease. <i>BMC Systems Biology</i> , 2014, 8, S8. | 3.0 | 24 |
| 71 | Lung-Function Trajectories and Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2015, 373, 1574-1575. | 27.0 | 23 |
| 72 | Plasma metabolomics and clinical predictors of survival differences in COPD patients. <i>Respiratory Research</i> , 2019, 20, 219. | 3.6 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Premature discontinuation during the UPLIFT study. <i>Respiratory Medicine</i> , 2011, 105, 1523-1530. | 2.9 | 20 |
| 74 | Common Genetic Variants Associated with Resting Oxygenation in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 51, 678-687. | 2.9 | 19 |
| 75 | Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. <i>European Respiratory Journal</i> , 2015, 46, 1501-1503. | 6.7 | 19 |
| 76 | Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. <i>European Journal of Internal Medicine</i> , 2021, 89, 3-9. | 2.2 | 19 |
| 77 | Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. <i>Respiratory Medicine</i> , 2013, 107, 1904-1911. | 2.9 | 18 |
| 78 | Future perspectives in COPD. <i>Respiratory Medicine</i> , 2005, 99, S41-S48. | 2.9 | 17 |
| 79 | Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. <i>Respiratory Research</i> , 2014, 15, 102. | 3.6 | 13 |
| 80 | Clinical and prognostic heterogeneity of C and D GOLD groups. <i>European Respiratory Journal</i> , 2015, 46, 250-254. | 6.7 | 11 |
| 81 | Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study. <i>International Journal of COPD</i> , 2016, 11, 1217. | 2.3 | 11 |
| 82 | Functional Capacity, Health Status, and Inflammatory Biomarker Profile in a Cohort of Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2015, 35, 348-355. | 2.1 | 8 |
| 83 | Differences in Health-Related Quality of Life Between New Mexican Hispanic and Non-Hispanic White Smokers. <i>Chest</i> , 2016, 150, 869-876. | 0.8 | 8 |
| 84 | Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. <i>International Journal of COPD</i> , 2011, 6, 269. | 2.3 | 6 |
| 85 | Shorter telomeres in non-smoking patients with airflow limitation. <i>Respiratory Medicine</i> , 2018, 138, 123-128. | 2.9 | 6 |
| 86 | Reply: Minimal or Maximal Clinically Important Difference: Using Death to Define MCID. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1392-1392. | 5.6 | 5 |
| 87 | Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFT® Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> Tj ETQq1 d.0.784314 rgBT /Ov | | |
| 88 | The EASI model: A first integrative computational approximation to the natural history of COPD. <i>PLoS ONE</i> , 2017, 12, e0185502. | 2.5 | 4 |
| 89 | Long-Acting β_2 -Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1641-1644. | 5.6 | 4 |
| 90 | Pharmacotherapy Impacts on COPD Mortality. <i>Archivos De Bronconeumologia</i> , 2021, 57, 5-6. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT [®] Randomized Controlled Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015, 2, 236-251. | 0.7 | 3 |
| 92 | Does Pharmacotherapy Reduce the Rate of Decline of Lung Function in COPD?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 171-172. | 5.6 | 2 |
| 93 | Reply: To COTE or Not to COTE: Generalizability, Validity, and Other Issues. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 805-805. | 5.6 | 2 |
| 94 | Documento de expertos del uso de broncodilatadores inhalados en monoterapia en el tratamiento de la EPOC estable leve-moderada. <i>Archivos De Bronconeumologia</i> , 2017, 53, 574-582. | 0.8 | 2 |
| 95 | ANTES: Un año después en la EPOC. <i>Archivos De Bronconeumologia</i> , 2022, 58, 291-294. | 0.8 | 1 |
| 96 | Lung Volume Reduction in Patients with COPD: Physiological and Clinical Implications. <i>Current Respiratory Medicine Reviews</i> , 2008, 4, 312-320. | 0.2 | 0 |
| 97 | Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , 2017, 53, 574-582. | 0.8 | 0 |
| 98 | The 7 Cardinal Sins of COPD in Spain. <i>Archivos De Bronconeumologia</i> , 2022, 58, 498-503. | 0.8 | 0 |
| 99 | Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASC Trial. <i>International Journal of COPD</i> , 2022, Volume 17, 273-282. | 2.3 | 0 |
| 100 | [Translated article] The ANTES Program in COPD: First Year. <i>Archivos De Bronconeumologia</i> , 2022, 58, T291-T294. | 0.8 | 0 |